<DOC>
	<DOCNO>NCT02948998</DOCNO>
	<brief_summary>Hypertrophic Cardiomyopathy ( HCM ) common hereditary heart disease high mortality . Heart failure common complication ( 50 % incidence ) patient . However , lack efficiency medicine treat heart failure HCM patient . Recent study find fibrosis common HCM patient progressive age . Late gadolinium enhancement cardiac magnetic resonance ( LGE-CMR ) gold standard measure leave ventricular ( LV ) fibrosis extent proven useful HCM patient . Aldosterone play important role development fibrosis . Meanwhile , study suggest aldosterone might participate development fibrosis HCM patient . Spironolactone , mineralocorticoid receptor antagonist , proven effect inceasing survival heart-failure patient eject fraction lower 35 % . Thus , investigator hypothesize fibrosis one important reason heart failure HCM patient . The purpose study investigate whether small dosage early prescription spironolactone HCM patient relieve and/or reverse fibrosis progress improve patient ' symptom . This study multicenter , randomize , control open-label study conduct 4 center Shanghai , China . The primary objective study evaluate efficacy spironolactone relieve LV fibrosis HCM patient . This study plan recruit 260 participant definite HCM diagnosis . Then participant randomize two group -- `` control group `` ( take spironolactone ) `` spironolactone group '' ( take 20mg spironolactone orally daily ) . LGE-CMR , echocardiography , 24-hour Holter , electrocardiography ( ECG ) , blood test ( include hemoglobin , creatitine , potassium , liver enzymes , proBNP , TnT , angiotensin aldosterone ) perform random allocation 2 year . LGE-CMR used measure extent fibrosis LV . The extent LGE+ % ( area show LGE divide total area ) 2-year experiment increase LGE+ % 2-year experiment compare control spironolactone group . Meanwhile , symptom , New York Heart Association classification cardiac function , arrhythmia , proBNP TnT etc . compare two group .</brief_summary>
	<brief_title>Evaluating Effect Spironolactone Hypertrophic Cardiomyopathy</brief_title>
	<detailed_description>Hypertrophic Cardiomyopathy ( HCM ) common hereditary heart disease . Approximate 1 -- 2 % population HCM patient die every year cardiocerebrovascular complication heart failure , stroke sudden cardiac death rank top three . Among , heart failure high incidence ( 50 % ) least way treat . Even though Heart Association United States Europe update guideline diagnosis management HCM , still lack qualified clinical trial medicine HCM real world . Late gadolinium enhancement cardiac magnetic resonance ( LGE-CMR ) gold standard measure leave ventricular ( LV ) fibrosis extent . Recent study find : ( 1 ) proportion HCM patient LV fibrosis early stage disease ; ( 2 ) LV fibrosis HCM patient progressive ; ( 3 ) 91.5 % population HCM patient late gadolinium enhancement ; ( 4 ) late gadolinium enchancement HCM patient related risk sudden death . Fibrosis important pathology heart failure patient coronary artery disease dilate cardiomyopathy . The activation renin-angiotensin-aldosterone system play key role progression heart failure . Small dosage spironolactone proven effect inceasing survival heart-failure patient eject fraction lower 35 % . Meanwhile , study find aldosterone level LV myocytes increase HCM patient HCM transgenic mouse . Furthermore , spironolactone , mineralocorticoid receptor antagonist , could reserve interstitial fibrosis , attenuate myocyte disarray 50 % , improve diastolic function HCM transgenic mouse . Thus , investigator hypothesize fibrosis one important reason heart failure HCM patient small dosage early prescription spironolactone HCM patient relieve and/or reverse fibrosis progress improve patient ' symptom . This study multicenter , randomize , control open-label study conduct 4 center Shanghai , China . The primary objective study evaluate efficacy spironolactone relieve LV fibrosis HCM patient . This study plan recruit 260 participant definite HCM diagnosis . Then participant randomize two group -- `` control group `` ( take spironolactone ) `` spironolactone group '' ( take 20mg spironolactone orally daily ) . LGE-CMR , echocardiography , 24-hour Holter , electrocardiography ( ECG ) , blood test ( include hemoglobin , creatitine , potassium , liver enzymes , proBNP , TnT , angiotensin aldosterone ) perform random allocation 2 year . LGE-CMR used measure extent fibrosis LV . Myocardial area show signal intensity ＞5 SD mean signal intensity normal myocardium define segment LGE . LGE extent segment express surface area show LGE divide total area give myocardial segment , summation planimetered LGE area short-axis slice yield total LGE extent , subsequently express proportion total LV myocardium ( LGE+ % ) . The extent LGE+ % 2-year experiment increase LGE+ % 2-year experiment compare control spironolactone group . Meanwhile , symptom , New York Heart Association classification cardiac function , arrhythmia , proBNP TnT etc . compare two group .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>male female , age 18 75 year wall thickness ≥15mm one LV myocardial segment measure image technique ( echocardiography , cardiac magnetic resonance imaging ( CMR ) compute tomography ( CT ) explain solely loading condition LVEF≥50 % serum potassium ＜5.0mmol/L systolic blood pressure ≥100mmHg take spironolactone last 6 month willing comply schedule visit inform consent form sign subject participation trial cardiac magnetic resonance imaging ( CMR ) accept spironolactone tolerant contradict take spironolactone last 6 month severe systemic illness life expectancy judge ＜ 3 year expect ventricular septal myectomy septal alcohol ablation trial expect valve repair replacement trial history myocardial infarction angiotensionconvertingenzyme inhibitor ( ACEI ) AT1 receptor blockade obligatory reason systolic blood pressure ＜90mmHg know orthostatic hypotension history hyperkalemia ( serum potassium ≥5.5mmol/L ) past 6 month serum potassium ≥5.0mmol/L within past 2 week severe renal dysfunction , define eGFR ＜30mL/min serum creatinine ≥221mmol/L hemodialysis know chronic hepatic disease , define aspartate aminotransferase alanine aminotransferase level ＞ 3 time upper limit normal read local laboratory woman childbearing lactation cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>